HC Wainwright reiterates Buy rating on Shattuck Labs
HC Wainwright & Co. analyst Joseph Pantginis has reaffirmed a Buy rating for Shattuck Labs, maintaining a price target of $18. The NASDAQ-listed stock (STTK) continues to receive positive outlook from the firm.
*this image is generated using AI for illustrative purposes only.
HC Wainwright & Co. analyst Joseph Pantginis has reaffirmed a Buy rating for Shattuck Labs. The firm maintains a price target of $18 for the stock, which is listed on NASDAQ under the ticker STTK. This reiteration follows a review of the company's position in the market.
The rating and price target underscore the analyst's continued confidence in Shattuck Labs' performance and future prospects. The $18 target provides a reference point for investors evaluating the stock's potential upside.
Analyst Details
The recommendation comes from Joseph Pantginis, an analyst at HC Wainwright & Co. The firm focuses on providing research and investment banking services, with Pantginis covering the biotechnology sector.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| HC Wainwright & Co. | Joseph Pantginis | Buy | $18 |
What upcoming clinical milestones could drive Shattuck Labs' stock toward the $18 price target?
How might Shattuck Labs' competitive position in the biotechnology sector evolve over the next year?
What are the potential risks or challenges that could hinder the company's growth trajectory?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
